GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular-Risk Individuals with Type 2 Diabetes

被引：0
|
作者：
Krishnaraj, Aishwarya
Park, Brady
Bakbak, Ehab
Verma, Raj
Quan, Adrian
Teoh, Hwee
Hess, David A.
Verma, Subodh
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-755-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
755-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Di scontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics
    Nelson, Adam J.
    Kaltenbach, Lisa A.
    Mcguire, Darren K.
    Levya, Monica
    Al-Khalidi, Hussein R.
    Webb, Laura
    Lopes, Renato D.
    Pop-Busui, Rodica
    Cavender, Matthew A.
    Aroda, Vanita R.
    Magwire, Melissa L.
    Richardson, Caroline R.
    Lingvay, Ildiko
    Kirk, Julienne K.
    Pandey, Ambarish
    Gaynor, Tanya
    Pak, Jonathan
    Washington, Alana
    Senyucel, Cagri
    Green, Jennifer B.
    Granger, Christopher B.
    Pagidipati, Neha J.
    AMERICAN HEART JOURNAL, 2025, 282 : 51 - 57
  • [42] LONG-TERM HEPATOPROTECTIVE EFFECTS OF GLP-1RA IN OBESE PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY
    Khataniar, Himsikhar
    Dharia, Ashni
    Desai, Aakash
    Butt, Muhammad Ali
    Babich, Michael
    Mohy-ud-din, Nabeeha
    HEPATOLOGY, 2024, 80
  • [43] Treatment Trends in Youth-Onset Type 2 Diabetes-Changing Landscape after GLP-1RA Approval
    Shin, Hojin
    Paik, Julie M.
    Wexler, Deborah J.
    Patorno, Elisabetta
    DIABETES, 2024, 73
  • [44] Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity
    Terenzi, Daniella C.
    Bakbak, Ehab
    Teoh, Hwee
    Krishnaraj, Aishwarya
    Puar, Pankaj
    Rotstein, Ori D.
    Cosentino, Francesco
    Goldenberg, Ronald M.
    Verma, Subodh
    Hess, David A.
    CARDIOVASCULAR RESEARCH, 2024, 119 (18) : 2858 - 2874
  • [45] Adherence to Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Patients with Type 2 Diabetes Mellitus (T2DM)
    Johnston, Stephen
    Nguyen, Hiep
    Felber, Eugene
    Cappell, Katherine
    Nelson, James K.
    Chu, Bong-Chul
    Kalsekar, Iftekhar
    DIABETES, 2014, 63 : A604 - A604
  • [46] Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes
    Vale, Catarina
    Lourenco, Ines Mariana
    Jordan, Gabriela
    Golovaty, Ilya
    Torres, Hugo
    Moin, Tannaz
    Buysschaert, Martin
    Neves, Joao Sergio
    Bergman, Michael
    DIABETES OBESITY & METABOLISM, 2024,
  • [47] Efficacy and safety of IDegLira (combination of insulin degludec plus liraglutide), in insulin-naive patients with type 2 diabetes uncontrolled on GLP-1 receptor agonist (GLP-1RA) therapy
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J. -P.
    Handelsman, Y.
    Lehmann, L. M.
    Mishra, A.
    Simpson, R. W.
    DIABETOLOGIA, 2015, 58 : S401 - S402
  • [48] Comparative Safety and Effectiveness of GLP-1RA and SGLT2i Use in Adults with Type 2 Diabetes in US Clinical Practice
    Hoffman, Sarah R.
    Lanes, Stephan
    Quimbo, Tracey
    Papazian, Aanahit
    White, Jeff
    Fisher, Vicki
    Cziraky, Mark J.
    Crowley, Matthew J.
    Willey, Vincent
    DIABETES, 2024, 73
  • [49] Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care
    Bonora, Benedetta Maria
    Rigato, Mauro
    Frison, Vera
    D'Ambrosio, Michele
    Tadiotto, Federica
    Lapolla, Annunziata
    Simioni, Natalino
    Paccagnella, Agostino
    Avogaro, Angelo
    Fadini, Gian Paolo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 173
  • [50] Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature
    Lisco, Giuseppe
    De Tullio, Anna
    Guastamacchia, Edoardo
    Triggiani, Vincenzo
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2021, 21 (04) : 626 - 646
12345